What is the latest published CME stock rating?

CME Group Inc. is shown with Reduce in the latest published report, analyzed 2026-05-20. The hub links directly to the full analysis surface where the dated rating, fair-value bridge, risks, and scorecard are documented together.

Where can I read the full CME analysis?

The full latest published report, analyzed 2026-05-20, lives at /stocks/CME/analysis. The bare ticker page summarizes that read and links to each analysis tab; earlier editions remain under /analysis/archive.

What fair value is used for CME?

The latest published report analyzed 2026-05-20 gives CME a fair value of USD 261 and a potential value of USD 341. These are dated research outputs, not live market prices; review the valuation assumptions, sensitivity analysis, and material risks before making a decision.

How often is the CME page updated?

The hub selects the latest published stock report regardless of age and displays its analysis date (2026-05-20). Separately sourced market data is labeled with its own recorded timestamp and is never inferred from the report.

CME Stock: Fundamentals & Analysis | StockMarketAgent.AI

Inloggen Start free

CME Group Inc. (CME)

NASDAQ: CME · USD

—

StockMarketAgent Research · Analyzed 2026-05-20

Our latest published analysis: CME rated Reduce

CME Group Inc.'s published Reduce conclusion compares the analysis-date price with fair value and potential value. Read the full report for assumptions, evidence, and material risks.

Fair value

$261 / share

Potential value

$341 / share

Upside to FV

-13.6%

Moat

9/10

Wide

Read full analysis →View archive · 24mo

9-phase methodology · same model in each published edition

Market cap	$109.6B
P/E (forward)	23.5x

Market data

Price

Recent price action with selectable time range.

Financial snapshot

P/E (forward): 23.5x
Market cap: $109.6B

Item	P1	P2	P3	P4	P5	Trend
Period	2021-12-31	2022-12-31	2023-12-31	2024-12-31	2025-12-31	Trend
Revenue	$4.69B	$5.02B	$5.58B	$6.13B	$6.52B	+8.6%
Gross profit	$3.85B	$4.27B	$4.75B	$5.28B	$5.61B	+9.9%
Operating income	$3.54B	$3.65B	$4.31B	$4.70B	$5.50B	+11.7%
Net income	$2.64B	$2.69B	$3.23B	$3.53B	$4.07B	+11.5%
EPS (diluted)	$7.29	$7.40	$8.86	$9.67	$11.16	+11.2%
EBITDA	$3.93B	$4.02B	$4.67B	$5.04B	$5.83B	+10.4%
R&D	—	—	—	—	—	—
SG&A	$151.7M	$137.4M	$144.4M	$132.7M	$150.5M	-0.2%

Ticker	Name	Market cap	P/E	P/S	ROIC	5Y rev CAGR	1Y total return	Rating
AAPL	Apple Inc.	—	—	—	—	—	—	Verkopen
ABNB	Airbnb, Inc.	—	—	—	—	—	—	Verkopen
ADBE	Adobe Inc.	—	—	—	—	—	—	Sterk kopen
ACGL	Arch Capital Group Ltd.	—	—	—	—	—	—	Sterk kopen
AIG	American International Group Inc.	—	—	—	—	—	—	Sterk kopen
AIZ	Assurant, Inc.	—	—	—	—	—	—	Aanhouden

Sensitivity: Ke × terminal growth

The highlighted base cell is anchored to composite fair-value midpoint ($261.16). It is the reference value for this grid, not a separate standalone fair-value claim.

Ke ↓ / g →	2.0%	2.5%	3.0%	3.5%	4.0%
7.1%	$313	$347	$389	$444	$457
8.1%	$261	$285	$313	$347	$389
9.1%	$224	$241	$261	$285	$313
10.1%	$196	$209	$224	$241	$261
11.1%	$175	$185	$196	$209	$224

Scorecard

Published factor rows and weighted composite

Valuation3.0

Management6.9

Balance Sheet7.0

Profitability7.5

Revenue Growth6.0

Risk Assessment8.5

Competitive Moat9.0

Earnings Quality7.5

Capital Efficiency4.5

Weighted composite

6.7/10

Above average

Category	Score	Reading
Valuation	3.0
Management	6.9
Balance Sheet	7.0
Profitability	7.5
Revenue Growth	6.0
Risk Assessment	8.5
Competitive Moat	9.0
Earnings Quality	7.5
Capital Efficiency	4.5

Ratinggeschiedenis

De rating die de gepubliceerde researcheditie van elke maand droeg. Een rating vergelijkt de koers op de analysedatum met de fair value; het is geen overzicht van of de inschatting juist bleek.

Jaar	jan	feb	mrt	apr	mei	jun	jul	aug	sep	okt	nov	dec
2026

CME Group Inc. (CME)

Our latest published analysis: CME rated Reduce

Price

Financial snapshot

Fair-value bridge

Latest news · CME

Valuation

Base and Bull scenarios

Sensitivity: Ke × terminal growth

Scorecard

Next earnings

Sector percentile context

Deeper analysis on CME

Frequently asked questions

Ratinggeschiedenis